Fig. 5: Novel HCN inhibitor MS7710 reverses CSDS-induced hyperdopaminergia in female CSDS-susceptible mice. | Molecular Psychiatry

Fig. 5: Novel HCN inhibitor MS7710 reverses CSDS-induced hyperdopaminergia in female CSDS-susceptible mice.

From: Design and validation of novel brain-penetrant HCN channel inhibitors to ameliorate social stress-induced susceptible phenotype

Fig. 5: Novel HCN inhibitor MS7710 reverses CSDS-induced hyperdopaminergia in female CSDS-susceptible mice.

a Experimental timeline for female CSDS and in vivo electrophysiology. b SI ratios of the female CSDS mice. c Example in vivo electrophysiology traces of firing rate in VTA DA neurons in female, CSDS-susceptible mice without MS7710 (0 mg/kg, baseline) and following a 1 mg/kg IP injection of MS7710 (scale bars 0.1 mV vs. 1 s). Summary and inset cumulative distribution (dotted horizontal line represents 100%) of: d Firing rate in VTA DA neurons during baseline conditions (0 mg/kg MS7710; n = 11/3) or post-IP injection of 1 mg/kg MS7710 (n = 16/3; ** p = 0.0010), and e bursting activity in VTA DA neurons during baseline conditions (0 mg/kg MS7710; n = 11/3) or post-IP injection of 1 mg/kg MS7710 (n = 16/3; * p = 0.0246). Notation of n = ntotal cells/ntotal mice. Data are presented as median ± quartiles ± min and max, analyzed by the Mann-Whitney test for two groups. * p < 0.05, ** p < 0.01.

Back to article page